DOJ ADA Settlement Involving Hepatitis B Sends Critical Message to Higher Ed and Medical Providers

by Saul Ewing Arnstein & Lehr LLP
Contact

Summary

The DOJ has concluded that two medical schools had no lawful basis for excluding applicants who had active cases of Hepatitis B because they could not show that these individuals posed a direct threat to the health and safety of others. The decision may have significant ramifications for higher education institutions, hospitals and other medical providers.

When the U.S. Department of Justice announced its recent ADA settlement with the University of Medicine and Dentistry of New Jersey (UMDNJ) it wanted to send a message to public and private Higher Ed institutions that "excluding people with disabilities from higher education based on unfounded fears or incorrect scientific information is unacceptable." The DOJ could easily have directed this message to all heath care providers, because this settlement involving two applicants with Hepatitis B is just the latest case, many involving health care providers, where DOJ has pursued claims on behalf of individuals who have been denied access to services because they were HIV-positive or had other medical conditions.

This March 5, 2013 settlement is particularly important to Higher Ed institutions, hospitals and other medical providers for two other reasons: (1) this is the first ADA settlement ever reached by DOJ on behalf of people with Hepatitis B (HBV) and (2) this appears to be the first time DOJ has said that covered entities can legally limit participation of health care practitioners with bloodbourne illnesses (HBV) in certain types of medical procedures, based upon viral load, if you follow current guidance from public health officials. The lessons from this settlement apply as well to any public entity covered under ADA Title II and to places of public accommodation covered under ADA Title III.

What Happened

What is known about the facts and the defenses is what is in the Settlement Agreement and DOJ's press release. In 2011, two individuals applied to, were offered and accepted admission to the UMDNJ School of Osteopathic Medicine, and one of them was also accepted to the UMDNJ School of Medicine. Both individuals submitted required medical and immunization forms that showed they had HBV. UMDNJ later rescinded both offers, but gave both applicants a one-year deferral option.

DOJ noted in its press release that both of the applicants came from the Asian American Pacific Islander community which, according to the CDC, makes up less than five percent of the total population in the United States, but accounts for more than 50 percent of Americans living with chronic HBV. Most of those individuals contracted HBV during childbirth.

UMDNJ said that it convened its standing HBV committee of medical experts to consider if the two applicants could, in light of their extremely high viral loads, safely perform the essential functions of a medical student without posing a direct threat to others. That committee concluded that the applicants would pose a direct threat to others. UMDNJ conceded during the investigation that this decision was based on the erroneous impression that students in both schools were required to perform "exposure-prone invasive procedures" as those terms were used in then-current guidelines of the Centers for Disease Control and Prevention (CDC). UMDNJ says it offered deferral in the hope that with medical treatment the applicants' viral loads of HBV would reduce below the level of a direct threat.

The "direct threat" defense has a long history that dates to case law under the Rehabilitation Act. The burden is on the entity raising this defense to show that there is a significant probability of serious harm to others that cannot be reduced through reasonable accommodations. Factors to be considered include the imminence, likelihood and severity of the risk. The determination of a direct threat must be made based upon objective medical evidence, and significant weight is accorded to the conclusions of public health officials.

DOJ's Findings

The DOJ concluded that the two schools had no lawful basis for excluding the applicants and could not show that these individuals posed a direct threat to the health and safety of others. The first reason, which UMDNJ admitted, is that the students at these schools were not required to perform invasive surgical procedures. Therefore, even under the older guidance that UMDNJ was using, the applicants should have been admitted.

The other reason DOJ gave in its press release is that the exclusion of these applicants contradicted the CDC's July 2012 "Updated Recommendations for Preventing Transmission and Medical Management of Hepatitis B Virus (HBV) – Infected Health Care Workers and Students." Among the CDC's findings was that no transmission of HBV from primary care providers, clinicians, medical or dental students, residents, nurses, or other health care providers to patients has been reported in the United States since 1991.

Higher Ed institutions, medical providers and other covered entities should note that the CDC's 2012 guidance was issued a year after the challenged admissions decisions. DOJ and the courts have placed a heavy burden on covered entities to show that individuals pose a direct threat. In cases involvingHBV, HIV and other communicable diseases, one important factor is whether there is evidence of a significant number of cases of transmission in a particular setting. With bloodbourne illnesses, covered entities must also address why Universal Precautions are not sufficient to address the risk. It appears that DOJ concluded the CDC's July 2012 guidelines reflected what was already accepted medical science.

Remedies

UMDNJ took action to mitigate the claims during the DOJ's investigation, so by the time of the settlement both applicants had been offered admission and one had been enrolled since August 2012. UMDNJ was ordered to pay each $20,000 and provide $17,500 in tuition credits to each of the applicants. DOJ did not impose any civil penalties on UMDNJ. While no explanation was given, this typically occurs when DOJ finds that a covered entity acted in good faith during the investigation, and acted in good faith and reasonably (even if in error) in its original decision.

Non-Discrimination and Viral Load

UMDNJ was ordered not to discriminate on the basis of disabilities, including HBV, in admission or other activities. The Settlement Agreement provides, however, that UMDNJ students with HBV viral loads of more than 5,000 genome equivalents per milliliter of blood can be legally prohibited from participating in any "Category I procedures" as defined by the new CDC guidelines. If UMDNJ decides to impose such restrictions, those students cannot face any resulting adverse action on their grades or evaluations of academic or clinical performance.

DOJ's Message to Higher Education Institutions

DOJ has limited resources. Each year numerous ADA complaints are sent to mediation (usually involving physical barriers at a single site) or not pursued. When DOJ chooses to investigate or pursue a claim, it is usually because the issue is on its priorities list or DOJ wants to send a message to a particular industry. In the DOJ's press release, Thomas E. Perez, Assistant Attorney General for the Civil Rights Division, sent the clear message that, "Excluding people with disabilities from higher education based on unfounded fears or incorrect scientific information is unacceptable." The U.S. Attorney for the District of New Jersey, Paul Fishman, added, "It is especially important that a public institution of higher learning – especially one with a mission to prepare future generations of medical professionals – strictly follow the laws Congress has enacted to protect from discrimination those people who have health issues."

Claims of Denial of Services Are a DOJ Priority

One of DOJ's current priorities is cases involving denial of services, especially involving HIV and now HBV. Last year DOJ settled a highly publicized case involving admission of a student with HIV to the private Milton Hershey School. (Saul Ewing defended the school in that case). Earlier in March, DOJ settled a case with an Alexandria, VA dentistry practice involving a decision to only treat a patient with HIV at the end of the day. Any complaint that a person has been denied admission to or access to the goods or services of a public or private entity, based solely on a medical condition, is likely to be made a priority case by DOJ for investigation.

Lessons for Hospitals, Health Care Providers and Others on Direct Threat

Another lesson from this and recent settlements is that DOJ will not defer to the judgment of medical providers on what is a direct threat to health and safety, especially when the conclusion is contrary to the most current literature and guidance of the CDC or other public health authorities. Covered entities that rely on older guidance do so at their own risk. On the other hand, where CDC and other authorities have found that there is a significant risk of transmission in certain settings, DOJ will defer to those conclusions under the direct threat standard. For more information regarding compliance with ADA Title II and III, Section 504 or similar laws prohibiting disability discrimination for any type of business, institution, association or public entity, or to learn about Saul Ewing's Higher Education Practice, contact Robert Duston at rduston@saul.com.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Saul Ewing Arnstein & Lehr LLP | Attorney Advertising

Written by:

Saul Ewing Arnstein & Lehr LLP
Contact
more
less

Saul Ewing Arnstein & Lehr LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.